Results presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2006 conference held in Washington, DC, by Rodney A White, Professor of Surgery at UCLA School of Medicine and Chief of Vascular Surgery at Harbor-UCLA Medical Center, highlighted favorable five-year follow-up data from Endologix’ Powerlink System pivotal clinical trial for the treatment of abdominal aortic aneurysm (AAA).
In his presentation ‘sac Remodeling After Endoluminal Grafting: Implications for Follow-up Surveillance and Treatment,’ White revealed that after five years of follow-up 97.9% of patients were free from AAA mortality, there were no aneurysm ruptures, there were no stent or graft material failures and 86.6% of patients were free from device-related secondary procedures.
“The clinical data for the Powerlink System is compelling. Endologix has set the bar as it pertains to the durability of the pivotal trial data set,” said White, “with a 95% compliance of eligible patient follow-up at five years as well as core lab 3-D modelling.”
